A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 Following Single Intravenous Administration
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Diridavumab (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza A virus infections
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 03 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to business reasons.
- 24 Dec 2013 New trial record